Mark Kaye
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
CNMD Featured in Low-Volatility Stock List. Conmed was included in a recent Yahoo Finance article highlighting three low-volatility stocks with questionable fundamentals. The piece suggests that while the stock may exhibit stable price movements, underlying financial metrics warrant closer scrutiny. This context is relevant for investors assessing the balance between the company's current valuation and its operational stability.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Moody's faces credit risk shift as rates rise, analysts adjust outlook. Moody's upgraded Egypt to a B3 rating, citing recent fiscal reforms and a positive outlook. The chief credit officer said higher interest rates are prompting a reassessment of credit risk across its portfolio. Analysts at JP Morgan kept an overweight stance but lowered their price target, reflecting the impact of rising Treasury yields on Moody's exposure. These developments show the firm adapting to a tighter rate environment while continuing sovereign rating activity.
Transaction History
| ELV | ▼ Sell | Tax Withholding | 4,161 | $1.6M | 10/2/2026 | View on chart |
| ELV | ▲ Buy | Grant | 2,627 | $0 | 10/2/2026 | View on chart |
| CNMD | ▲ Buy | Option Exercise | 668 | $0 | 6/2/2026 | View on chart |
| ELV | ▼ Sell | Tax Withholding | 353 | $100K | 3/3/2026 | View on chart |
| ELV | ▼ Sell | Tax Withholding | 271 | $80K | 3/2/2026 | View on chart |
| ELV | ▲ Buy | Grant | 6,377 | $0 | 3/2/2026 | View on chart |
| ELV | ▲ Buy | Grant | 10,202 | $0 | 3/2/2026 | View on chart |
| CNMD | ▲ Buy | Option Exercise | 152 | $0 | 2/24/2026 | View on chart |
| ELV | ▼ Sell | Tax Withholding | 2,895 | $985K | 10/2/2025 | View on chart |
| ELV | ▼ Sell | Open Market | 4,588 | $1.9M | 4/24/2025 | View on chart |
| ELV | ▼ Sell | Tax Withholding | 270 | $107K | 3/3/2025 | View on chart |
| ELV | ▲ Buy | Grant | 3,604 | $0 | 3/3/2025 | View on chart |
| ELV | ▼ Sell | Tax Withholding | 2,818 | $1.4M | 10/2/2024 | View on chart |
| ELV | ▲ Buy | Grant | 2,755 | $0 | 3/1/2024 | View on chart |
| ELV | ▲ Buy | Grant | 2,102 | $0 | 10/2/2023 | View on chart |
| ELV | ▲ Buy | Grant | 18,174 | $0 | 10/2/2023 | View on chart |
| MCO | ▼ Sell | Open Market | 3,832 | $1.3M | 8/7/2023 | View on chart |
| MCO | ▲ Buy | Option Exercise | 1,741 | $302K | 8/7/2023 | View on chart |
| MCO | ▼ Sell | Open Market | 1,741 | $594K | 8/7/2023 | View on chart |
| MCO | ▲ Buy | Option Exercise | 3,470 | $973K | 8/7/2023 | View on chart |
| MCO | ▼ Sell | Open Market | 3,470 | $1.2M | 8/7/2023 | View on chart |
| MCO | ▲ Buy | Option Exercise | 714 | $198K | 8/7/2023 | View on chart |
| MCO | ▲ Buy | Option Exercise | 3,857 | $1.1M | 8/7/2023 | View on chart |
| MCO | ▼ Sell | Open Market | 3,857 | $1.3M | 8/7/2023 | View on chart |
| MCO | ▲ Buy | Option Exercise | 1,544 | $503K | 8/7/2023 | View on chart |
| MCO | ▼ Sell | Open Market | 1,544 | $526K | 8/7/2023 | View on chart |
| MCO | ▼ Sell | Open Market | 714 | $244K | 8/7/2023 | View on chart |
| MCO | ▼ Sell | Tax Withholding | 43 | $15K | 7/3/2023 | View on chart |
| MCO | ▼ Sell | Open Market | 975 | $310K | 5/19/2023 | View on chart |
| MCO | ▼ Sell | Tax Withholding | 3,426 | $996K | 3/1/2023 | View on chart |
| MCO | ▲ Buy | Grant | 5,537 | $0 | 3/1/2023 | View on chart |
| MCO | ▲ Buy | Grant | 1,845 | $545K | 2/21/2023 | View on chart |
| MCO | ▲ Buy | Option Exercise | 1,740 | $302K | 8/15/2022 | View on chart |
| MCO | ▲ Buy | Option Exercise | 1,374 | $215K | 8/15/2022 | View on chart |
| MCO | ▼ Sell | Open Market | 1,374 | $443K | 8/15/2022 | View on chart |
| MCO | ▼ Sell | Open Market | 1,740 | $561K | 8/15/2022 | View on chart |
| MCO | ▼ Sell | Tax Withholding | 43 | $12K | 7/1/2022 | View on chart |
| MCO | ▼ Sell | Open Market | 3,702 | $1.2M | 3/2/2022 | View on chart |
| MCO | ▼ Sell | Tax Withholding | 4,379 | $1.4M | 3/1/2022 | View on chart |
| MCO | ▲ Buy | Grant | 7,285 | $0 | 3/1/2022 | View on chart |
| MCO | ▲ Buy | Grant | 1,595 | $520K | 2/17/2022 | View on chart |
| MCO | ▼ Sell | Open Market | 316 | $126K | 11/18/2021 | View on chart |
| MCO | ▼ Sell | Open Market | 1,043 | $396K | 8/16/2021 | View on chart |
| MCO | ▲ Buy | Option Exercise | 1,734 | $486K | 8/16/2021 | View on chart |
| MCO | ▼ Sell | Open Market | 1,734 | $658K | 8/16/2021 | View on chart |
| MCO | ▲ Buy | Option Exercise | 356 | $99K | 8/16/2021 | View on chart |
| MCO | ▼ Sell | Open Market | 356 | $135K | 8/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Elevance Health Q3 Outlook: Premium Pressures and Sector Peer Trends
Elevance Health is preparing for its third-quarter earnings report, with analysts examining key metrics and the potential impact of lower premiums on the company's results. Broader sector news highlights peers like UnitedHealth, Centene, and Oscar Health pursuing growth and cost-saving strategies amidst shifting premium dynamics. The market is observing how these competitive and industry-wide pressures will align with Elevance Health's upcoming performance.
Elevance Health Q3 Outlook: Premium Pressures and Sector Peer Trends. Elevance Health is preparing for its third-quarter earnings report, with analysts examining key metrics and the potential impact of lower premiums on the company's results. Broader sector news highlights peers like UnitedHealth, Centene, and Oscar Health pursuing growth and cost-saving strategies amidst shifting premium dynamics. The market is observing how these competitive and industry-wide pressures will align with Elevance Health's upcoming performance.